1-3 of 3
Shady I. Tantawy
Close
Sort by
Journal Articles

Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study

Jennifer R. Brown, Sai Prasad Desikan, Bastien Nguyen, Helen Won, Shady I. Tantawy, Samuel McNeely, Narasimha Marella, Kevin Ebata, Jennifer A. Woyach, Krish Patel, Constantine S. Tam, Toby A. Eyre, Chan Y. Cheah, Nirav N. Shah, Paolo Ghia, Wojciech Jurczak, Minna Balbas, Binoj Nair, Paolo Abada, Chunxiao Wang, Ying (Denise) Wang, Lindsey E. Roeker, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 326.
https://doi.org/10.1182/blood-2023-180143
Published: 2023
Journal Articles

Characterization and Preclinical Evaluation of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Chronic Lymphocytic Leukemia

Shady I. Tantawy, Natalia Timofeeva, Hitomi Fujiwara, Mariko Hatakeyama, Breana Herrera, Lizbeth Loza, Tokiko Asami, Hiroshi Ohmoto, Kyoko Miyamoto, Yu Nishioka, Akinori Arimura, Masaaki Sawa, Nitin Jain, Varsha Gandhi
Journal: Blood
Blood (2023) 142 (Supplement 1): 1453.
https://doi.org/10.1182/blood-2023-189659
Published: 2023
Journal Articles

Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib

Shady I. Tantawy, Burcu Aslan, Lisa S Chen, Lakesla Iles, Philip A. Thompson, Nitin Jain, William G. Wierda, Varsha Gandhi
Journal: Blood
Blood (2022) 140 (Supplement 1): 501–502.
https://doi.org/10.1182/blood-2022-171119
Published: 2022